Mohamed Naguib
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mohamed Naguib has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Abdulhamid H. Samarkandi
King Saud University, College of Medicine at King Khalid University Hospital
3 shared publicationsMagboul M. A. Magboul
King Khalid University Hospital
2 shared publicationsMounir Attia
King Saud University, College of Medicine at King Khalid University Hospital
2 shared publicationsA Magboul
1 shared publicationA. Ammar
1 shared publicationA. H. Samarkandi
1 shared publication
Latest Publications
- Open Access
- 1 August 1999
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 91 (2) , 588
Rocuronium-Cisatracurium Combinations
- 1 August 1999
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 91 (2) , 588
Open AccessRocuronium-Cisatracurium Combinations
- 1 December 1998
- Published by Springer Nature in Canadian Journal of Anesthesia/Journal canadien d'anesthésie
- Vol. 45 (12) , 1168-1175
Perioperative antinociceptive effects of tramadol. A prospective, randomized, double-blind comparison with morphine
To compare the efficacy of tramadol and morphine for intra-and postoperative analgesia in patients undergoing laparoscopic cholecystectomy. In a prospective, randomized, double-blind study 100 patients were allocated randomly into two groups. Ten minutes before induction of anaesthesia, patients in group I received 100 mg tramadol and those in group 2 received 10 mg morphineiv. Anaesthesia was induced with 5 mg·kg−1 thiopental and was maintained with O2, N2O plus isoflurane with additional doses of tramadol or morphine as decided by the attending anaesthetist. Postoperatively, patients in group I and group 2 received tramadol and morphine, respectively, from a patient-controlled analgesia (PCA) device. Pain, analgesic consumption, vital signs and side effects were recorded postoperatively for 24 hr. Intraoperative consumption of tramadol and morphine were 137 ± 37 and 12.2 ± 3 mg, respectively. Compared with morphine, patients receiving tramadol had higher blood pressures and required greater mean ETiso to control haemodynamic variables (P < 0.05). Postoperatively, there were no differences in observer pain score or visual analogue pain score during the first 24 hr between groups except at 30, 45, and 90 min where patients in the tramadol group reported higher pain scores (P < 0.05). The cumulative, 24 hr PCA consumption was III ± 93 and 7.5 ± 6.6 mg of tramadol and morphine, respectively. There was no difference between the use of tramadol and morphine to treat pain after laparoscopic cholecystectomy from 90 min after the end of surgery. Morphine was more effective than tramadol as an intraoperative analgesic. Comparer l’efficacité du tramadol et de la morphine pour l’analgésie peropératoire et postopératoire de patients devant subir une cholécystectomie laparoscopique. Lors d’une étude prospective, randomisée et en double aveugle, 100 patients ont été répartis au hasard en deux groupes. Dix minutes avant l’induction de l’anesthésie, les patients du groupe I ont reçu 100 mg de tramadol et ceux du groupe 2, 10 mg de morphineiv. Lanesthésie a été induite avec 5 mg·kg−1 de thiopental et a été maintenue avec un mélange d’O2 et de N2O plus de l’isoflurane et des doses supplémentaires de tramadol ou de morphine selon la décision de l’anesthésiste traitant. Après l’intervention, les patients des groupes 1 et 2 ont reçu respectivement du tramadol et de la morphine à l’aide d’un dispositif d’analgésie contrôlée par le patient (ACP). En période postopératoire également, on a enregistré pendant 24 heures la douleur, la consommation d’analgésiques, les signes vitaux et les effets secondaires. La consommation peropératoire de tramadol et de morphine a été de 137 ± 37 et de 12,2 ± 3 mg, respectivement. Comparativement, les patients qui ont reçu du tramadol ont présenté une tension artérielle plus élevée et ont eu besoin d’isofluraneTE (télé-expiratoire) de moyenne plus élevée pour contrôler les variables hémo-dynamiquesP < 0,05). Il n’y a pas eu de différence de douleur postopératoire entre les groupes d’après les niveaux enregistrés par un observateur ou par l’échelle visuelle analogique, pendant les 24 premières heures, sauf à 30, 45 et 90 min alors que les patients du groupe ayant reçu du tramadol ont éprouvé des douleurs plus intenses (P < 0,05). La consommation totale des 24 h d’ACP a été de 111 ±93 et de 7,5 ± 6,6 mg de tramadol et de morphine, respectivement. À partir de 90 min après la chirurgie, il n’y a pas de différence entre l’usage de tramadol ou de morphine pour traiter la douleur consécutive à la cholécystectomie laparoscopique. La morphine a été plus efficace que le tramadol en tant qu’analgésique peropératoire.
- 1 December 1998
- Published by Springer Nature in Canadian Journal of Anesthesia/Journal canadien d'anesthésie
- Vol. 45 (12) , 1168-1175
Perioperative antinociceptive effects of tramadol. A prospective, randomized, double-blind comparison with morphine
To compare the efficacy of tramadol and morphine for intra-and postoperative analgesia in patients undergoing laparoscopic cholecystectomy. In a prospective, randomized, double-blind study 100 patients were allocated randomly into two groups. Ten minutes before induction of anaesthesia, patients in group I received 100 mg tramadol and those in group 2 received 10 mg morphineiv. Anaesthesia was induced with 5 mg·kg−1 thiopental and was maintained with O2, N2O plus isoflurane with additional doses of tramadol or morphine as decided by the attending anaesthetist. Postoperatively, patients in group I and group 2 received tramadol and morphine, respectively, from a patient-controlled analgesia (PCA) device. Pain, analgesic consumption, vital signs and side effects were recorded postoperatively for 24 hr. Intraoperative consumption of tramadol and morphine were 137 ± 37 and 12.2 ± 3 mg, respectively. Compared with morphine, patients receiving tramadol had higher blood pressures and required greater mean ETiso to control haemodynamic variables (P < 0.05). Postoperatively, there were no differences in observer pain score or visual analogue pain score during the first 24 hr between groups except at 30, 45, and 90 min where patients in the tramadol group reported higher pain scores (P < 0.05). The cumulative, 24 hr PCA consumption was III ± 93 and 7.5 ± 6.6 mg of tramadol and morphine, respectively. There was no difference between the use of tramadol and morphine to treat pain after laparoscopic cholecystectomy from 90 min after the end of surgery. Morphine was more effective than tramadol as an intraoperative analgesic. Comparer l’efficacité du tramadol et de la morphine pour l’analgésie peropératoire et postopératoire de patients devant subir une cholécystectomie laparoscopique. Lors d’une étude prospective, randomisée et en double aveugle, 100 patients ont été répartis au hasard en deux groupes. Dix minutes avant l’induction de l’anesthésie, les patients du groupe I ont reçu 100 mg de tramadol et ceux du groupe 2, 10 mg de morphineiv. Lanesthésie a été induite avec 5 mg·kg−1 de thiopental et a été maintenue avec un mélange d’O2 et de N2O plus de l’isoflurane et des doses supplémentaires de tramadol ou de morphine selon la décision de l’anesthésiste traitant. Après l’intervention, les patients des groupes 1 et 2 ont reçu respectivement du tramadol et de la morphine à l’aide d’un dispositif d’analgésie contrôlée par le patient (ACP). En période postopératoire également, on a enregistré pendant 24 heures la douleur, la consommation d’analgésiques, les signes vitaux et les effets secondaires. La consommation peropératoire de tramadol et de morphine a été de 137 ± 37 et de 12,2 ± 3 mg, respectivement. Comparativement, les patients qui ont reçu du tramadol ont présenté une tension artérielle plus élevée et ont eu besoin d’isofluraneTE (télé-expiratoire) de moyenne plus élevée pour contrôler les variables hémo-dynamiquesP < 0,05). Il n’y a pas eu de différence de douleur postopératoire entre les groupes d’après les niveaux enregistrés par un observateur ou par l’échelle visuelle analogique, pendant les 24 premières heures, sauf à 30, 45 et 90 min alors que les patients du groupe ayant reçu du tramadol ont éprouvé des douleurs plus intenses (P < 0,05). La consommation totale des 24 h d’ACP a été de 111 ±93 et de 7,5 ± 6,6 mg de tramadol et de morphine, respectivement. À partir de 90 min après la chirurgie, il n’y a pas de différence entre l’usage de tramadol ou de morphine pour traiter la douleur consécutive à la cholécystectomie laparoscopique. La morphine a été plus efficace que le tramadol en tant qu’analgésique peropératoire.
- 1 November 1998
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 89 (5) , 1116-1124
Comparative Clinical Pharmacology of Rocuronium, Cisatracurium, and Their Combination
Background: The comparative clinical pharmacology of cisatracurium and rocuronium and their combinations has not been reported. In this study, the authors compared the relative potency and the clinical profile and characterized the interaction of both drugs. Methods: Two hundred twenty adults classified as American Society of Anesthesiologists physical status I and anesthetized with propofol-fentanyl-nitrous oxide were studied. In part 1, the neuromuscular-blocking effects of cisatracurium and rocuronium were assessed after administration of bolus doses of 20-50 microg/kg and 100-300 microg/kg, respectively. In part 2, we compared the time course of 1xED50, 1, 1.5, and 2xED95 doses of both drugs (where ED50 and ED95 are, respectively, the doses producing 50% and 95% depression of the first twitch height [T1]). In part 3, equieffective combinations of both drugs were studied to characterize their interaction. Results: The calculated ED50 values and their 95% confidence intervals were 111 (107-115) and 26.2 (25.8-26.5) microg/kg [corrected] for rocuronium and cisatracurium, respectively. Compared with equipotent doses of cisatracurium, rocuronium had a faster onset, and a faster spontaneous T1 and train-of-four recovery times that were significant except at maximum recovery with the 2xED95 dose. The interaction between rocuronium and cisatracurium was synergistic, and the time profile of the combination group was different from that of the single-dose groups. Conclusions: Cisatracurium is four to five times more potent than rocuronium. Rocuronium had a faster onset of action, a shorter clinical duration, and a faster spontaneous recovery rate compared with equipotent doses of cisatracurium.
- 1 November 1998
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 89 (5) , 1116-1124
Comparative Clinical Pharmacology of Rocuronium, Cisatracurium, and Their Combination
Background: The comparative clinical pharmacology of cisatracurium and rocuronium and their combinations has not been reported. In this study, the authors compared the relative potency and the clinical profile and characterized the interaction of both drugs. Methods: Two hundred twenty adults classified as American Society of Anesthesiologists physical status I and anesthetized with propofol-fentanyl-nitrous oxide were studied. In part 1, the neuromuscular-blocking effects of cisatracurium and rocuronium were assessed after administration of bolus doses of 20-50 microg/kg and 100-300 microg/kg, respectively. In part 2, we compared the time course of 1xED50, 1, 1.5, and 2xED95 doses of both drugs (where ED50 and ED95 are, respectively, the doses producing 50% and 95% depression of the first twitch height [T1]). In part 3, equieffective combinations of both drugs were studied to characterize their interaction. Results: The calculated ED50 values and their 95% confidence intervals were 111 (107-115) and 26.2 (25.8-26.5) microg/kg [corrected] for rocuronium and cisatracurium, respectively. Compared with equipotent doses of cisatracurium, rocuronium had a faster onset, and a faster spontaneous T1 and train-of-four recovery times that were significant except at maximum recovery with the 2xED95 dose. The interaction between rocuronium and cisatracurium was synergistic, and the time profile of the combination group was different from that of the single-dose groups. Conclusions: Cisatracurium is four to five times more potent than rocuronium. Rocuronium had a faster onset of action, a shorter clinical duration, and a faster spontaneous recovery rate compared with equipotent doses of cisatracurium.
- 1 June 1998
- Vol. 14 (5) , 341-73
Adverse effects of neuromuscular blockers and their antagonists.
Among all the drugs used for general anesthesia, neuromuscular blockers appear to play a prominent role in the incidence of severe adverse reactions. It now seems likely that most serious adverse drug reactions occurring during anesthesia are immunological in type. The frequency of life-threatening anaphylactic or anaphylactoid reactions occurring during anesthesia has been estimated to be between 1 in 1000 and 1 in 25,000 anesthetic procedures, with the neuromuscular blockers being involved in 80% of cases. The mortality from such serious reactions is reported to be in the range of 3.4 to 6%. The highly immunogenic drug, suxamethonium chloride (succinylcholine), was found to be the most hazardous agent. Drug-specific immunoglobulin E antibodies to suxamethonium chloride and other neuromuscular blockers have been demonstrated. This sensitivity to neuromuscular blockers seems to be a long-lasting phenomenon. During anesthesia, the clinical features of an allergic reaction are often masked. Tachycardia and circulatory collapse may be the only signs of an allergic reaction, and they are easily misdiagnosed. Bronchospasm is reported to be present in about 40% of cases. Successful management of these patients includes stabilisation during the acute reaction and avoidance of future reactions. The latter is based on the identification of the causative drug and potentially cross-reacting compounds. The use of suxamethonium chloride is associated with many other adverse effects, such as fasciculations, myalgia, potassium release, changes in the heart rate, increases in intragastric and intraocular pressures, and malignant hyperthermia. Because of the dangers of hyperkalemic cardiac arrest suxamethonium chloride administration in children with unrecognised muscular dystrophy, there have now been moves to limit the use of this drug in children. Although neuromuscular blockers are designed to specifically block nicotinic cholinergic receptors at the neuromuscular junction, many bind to muscarinic cholinergic receptors on ganglia and smooth muscle, and alter parasympathetically mediated heart rate and airway calibre. Most benzylisoquinolinium muscle relaxants can induce histamine release, especially when they are administered rapidly, which can lead to disturbances of cardiovascular function. In addition, nondepolarising neuromuscular blockers have been implicated in causing generalised weakness following their long term administration to patients on an intensive care unit. The problem with these adverse drug reactions is their upredictable nature. Therefore, prompt recognition with appropriate therapy can help to improve the outcome.
- 1 June 1998
- Vol. 14 (5) , 341-73
Adverse effects of neuromuscular blockers and their antagonists.
Among all the drugs used for general anesthesia, neuromuscular blockers appear to play a prominent role in the incidence of severe adverse reactions. It now seems likely that most serious adverse drug reactions occurring during anesthesia are immunological in type. The frequency of life-threatening anaphylactic or anaphylactoid reactions occurring during anesthesia has been estimated to be between 1 in 1000 and 1 in 25,000 anesthetic procedures, with the neuromuscular blockers being involved in 80% of cases. The mortality from such serious reactions is reported to be in the range of 3.4 to 6%. The highly immunogenic drug, suxamethonium chloride (succinylcholine), was found to be the most hazardous agent. Drug-specific immunoglobulin E antibodies to suxamethonium chloride and other neuromuscular blockers have been demonstrated. This sensitivity to neuromuscular blockers seems to be a long-lasting phenomenon. During anesthesia, the clinical features of an allergic reaction are often masked. Tachycardia and circulatory collapse may be the only signs of an allergic reaction, and they are easily misdiagnosed. Bronchospasm is reported to be present in about 40% of cases. Successful management of these patients includes stabilisation during the acute reaction and avoidance of future reactions. The latter is based on the identification of the causative drug and potentially cross-reacting compounds. The use of suxamethonium chloride is associated with many other adverse effects, such as fasciculations, myalgia, potassium release, changes in the heart rate, increases in intragastric and intraocular pressures, and malignant hyperthermia. Because of the dangers of hyperkalemic cardiac arrest suxamethonium chloride administration in children with unrecognised muscular dystrophy, there have now been moves to limit the use of this drug in children. Although neuromuscular blockers are designed to specifically block nicotinic cholinergic receptors at the neuromuscular junction, many bind to muscarinic cholinergic receptors on ganglia and smooth muscle, and alter parasympathetically mediated heart rate and airway calibre. Most benzylisoquinolinium muscle relaxants can induce histamine release, especially when they are administered rapidly, which can lead to disturbances of cardiovascular function. In addition, nondepolarising neuromuscular blockers have been implicated in causing generalised weakness following their long term administration to patients on an intensive care unit. The problem with these adverse drug reactions is their upredictable nature. Therefore, prompt recognition with appropriate therapy can help to improve the outcome.
- 1 January 1998
- Published by Springer Nature in Drug Safety
- Vol. 18 (2) , 99-116
Adverse Effects of Neuromuscular Blockers and Their Antagonists
Among all the drugs used for general anaesthesia, neuromuscular blockers appear to play a prominent role in the incidence of severe adverse reactions. It now seems likely that most serious adverse...
- 1 January 1998
- Published by Springer Nature in Drug Safety
- Vol. 18 (2) , 99-116
Adverse Effects of Neuromuscular Blockers and Their Antagonists
Among all the drugs used for general anaesthesia, neuromuscular blockers appear to play a prominent role in the incidence of severe adverse reactions. It now seems likely that most serious adverse...
- 1 January 1998
- Published by Springer Nature in Drug Safety
- Vol. 18 (4) , 221-250
Adverse Effects and Drug Interactions Associated with Local and Regional Anaesthesia
Systemic and localised adverse effects of local anaesthetic drugs usually occur because of excessive dosage, rapid absorption or inadvertent intravascular injection. Small children are more prone than...
- 1 January 1998
- Published by Springer Nature in Drug Safety
- Vol. 18 (4) , 221-250
Adverse Effects and Drug Interactions Associated with Local and Regional Anaesthesia
Systemic and localised adverse effects of local anaesthetic drugs usually occur because of excessive dosage, rapid absorption or inadvertent intravascular injection. Small children are more prone than...
- 1 September 1997
- Published by Wolters Kluwer Health in European Journal of Anaesthesiology
- Vol. 14 (Supplement) , 35
Comparison of suxamethonium and different combinations of rocuronium and mivacurium for rapid sequence induction of anaesthesia in children
- 1 September 1997
- Published by Wolters Kluwer Health in European Journal of Anaesthesiology
- Vol. 14 (Supplement) , 35
Comparison of suxamethonium and different combinations of rocuronium and mivacurium for rapid sequence induction of anaesthesia in children